Compounded Semaglutide After the Shortage: What Patients Need to Know

For nearly three years, the national shortage of semaglutide — the active ingredient in Ozempic and Wegovy — allowed licensed compounding pharmacies to legally manufacture and dispense their own versions of the drug. That chapter officially closed in March 2025, when the U.S. Food and Drug Administration removed semaglutide from its Drug Shortage Database and declared the shortage resolved. The consequences for patients already relying on compounded semaglutide are significant, confusing, and still unfolding.

This guide breaks down exactly what the FDA's declaration means, who it affects, what your legal options are, and how to talk to your prescriber about the path forward.

The Semaglutide Shortage: A Brief Timeline

Semaglutide first appeared on the FDA Drug Shortage Database in March 2022driven by explosive demand following the approvals of Ozempic (for type 2 diabetes, 2017) and Wegovy (for chronic weight management, 2021). Novo Nordisk, the sole manufacturer of branded semaglutide products, could not keep pace with prescriptions that were growing hundreds of percent year over year.

The shortage triggered a legal exemption under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act: when a drug is on the FDA shortage list, compounding pharmacies are permitted to prepare copies of that drug — even if it duplicates a commercially available product. This exemption opened the door for hundreds of compounding pharmacies to begin producing semaglutide injections and oral formulations, often at a fraction of the brand-name cost.

At its peak in 2023–2024, the compounded semaglutide market was estimated to represent hundreds of millions of dollars in monthly saleswith major telehealth platforms offering injectable semaglutide for $150–$400 per month versus Wegovy's retail price of approximately $1,349/month.

In March 2025the FDA officially removed semaglutide from the shortage list, declaring that Novo Nordisk had achieved adequate supply to meet national demand. That declaration triggered a compliance deadline: compounding pharmacies were given a limited wind-down period — initially 60 to 90 days — to stop producing compounded semaglutide.

What "Shortage Over" Actually Means — Legally

The FDA's shortage removal does not mean compounded semaglutide was declared unsafe or ineffective. It means the legal justification for compounding a copy of a commercially available drug no longer applies.

Under federal law, compounding pharmacies cannot produce copies of FDA-approved drugs when those drugs are adequately available in the market — a rule designed to prevent compounders from undercutting brand manufacturers. Once semaglutide left the shortage list, compounding it became a violation of the Food, Drug, and Cosmetic Act for most pharmacies.

There are critical distinctions, however:

• 503A pharmacies (traditional compounders) may still compound semaglutide for patients with a documented, individualized need that cannot be met by the commercial product — such as a specific allergy to an inactive ingredient, or a need for a dose not commercially available. This must be supported by a valid prescription from a licensed prescriber.
• 503B outsourcing facilities (larger, FDA-registered compounders that produce in bulk for healthcare facilities) have stricter rules and generally cannot continue compounding a non-shortage drug without FDA authorization.
• Semaglutide salts (such as semaglutide sodium or semaglutide acetate) have been argued by some pharmacies to be distinct from the base compound in branded products. The FDA has pushed back strongly on this interpretation, sending warning letters to companies marketing these formulations as legally distinct.

Brand-Name Availability and Cost Realities

The declaration that the shortage is "over" assumes patients can access brand-name Wegovy or Ozempic. But clinical reality is more complicated.

As of 2025, Wegovy retails for approximately $1,349/month without insurance. Ozempic, while FDA-approved only for diabetes, is often prescribed off-label for weight management and carries a similar price point. Commercial insurance coverage for Wegovy varies widely — roughly 50% of large employer plans cover it, while Medicare Part D explicitly excludes weight-loss medications (pending passage of the Treat and Reduce Obesity Act, or TROA). Medicaid coverage is state-by-state and inconsistent.

Novo Nordisk offers a manufacturer savings card that can reduce costs to as low as $0/month for eligible commercially insured patientsbut uninsured or Medicare patients are largely excluded. The practical result is that millions of patients who were stabilized on compounded semaglutide face a sharp financial cliff.

What Patients Currently on Compounded Semaglutide Should Do

If you've been using compounded semaglutide through a telehealth provider or compounding pharmacy, here is the practical guidance:

1. Don't Stop Abruptly Without Talking to Your Provider

Discontinuing semaglutide suddenly can result in weight regain — clinical trial data from the STEP 4 trial (Wilding et al., 2022) demonstrated that patients who stopped semaglutide regained approximately two-thirds of lost weight within 12 months. Your prescriber can help you plan a responsible transition.

2. Check Your Insurance Coverage for Wegovy

Contact your insurance plan directly to confirm whether Wegovy is on formulary, what tier it sits at, and whether prior authorization or step therapy is required. Many plans that do cover Wegovy require a documented history of failed weight-loss attempts or a qualifying BMI (typically ≥30, or ≥27 with a comorbidity).

3. Ask About the Novo Nordisk Savings Program

If you have commercial (employer or marketplace) insurance, you may qualify for the Wegovy savings card, which caps your cost at $0 or a low copay for a defined period. Your prescriber's office or the NovoCare patient assistance line can help determine eligibility.

4. Explore Tirzepatide (Zepbound)

Eli Lilly's tirzepatide (brand name Zepbound for weight management) is a GLP-1/GIP dual agonist that has demonstrated superior weight loss in head-to-head data versus semaglutide — the SURMOUNT-5 trial (2024) showed ~20.2% vs ~13.7% body weight reduction at 72 weeks. Importantly, tirzepatide remains on the FDA shortage list as of early 2025, meaning compounded tirzepatide is still legally available through compliant pharmacies.

5. Confirm Your Pharmacy's Compliance Status

If a compounding pharmacy is still offering semaglutide after the wind-down deadline, ask them specifically on what legal basis they are continuing. If they cannot provide a clear answer citing a documented patient-specific need under 503A, the product may not be legally manufactured, and quality oversight may be compromised.

Compounded vs. Brand-Name: What We Know About Safety

The FDA has consistently stated that compounded semaglutide products are not FDA-approved and have not undergone the same clinical testing, manufacturing standards review, or safety monitoring as Wegovy and Ozempic. In 2024, the FDA issued multiple warning letters and identified compounded semaglutide products containing incorrect dosages and unlisted ingredients.

That said, 503A pharmacies operating under valid state boards of pharmacy are subject to USP compounding standardsand many patients tolerated compounded formulations without incident. The distinction the FDA draws is one of oversight and accountability, not an automatic assumption that all compounded product is unsafe.

Patients who experienced good tolerability and outcomes on compounded semaglutide are unlikely to see a clinical difference if they transition to Wegovy — the active molecule is identical. The practical barriers are cost and access, not pharmacology.

Telehealth Platforms and What's Changing

The major direct-to-consumer telehealth platforms that built their business models around compounded semaglutide have been forced to adapt. Some have transitioned to brand-name Wegovy prescriptions for insured patients, some now focus on compounded tirzepatide, and others offer combination metabolic programs that don't rely solely on GLP-1 medications.

Reputable telehealth providers will be transparent about what they're prescribing, which pharmacy fulfills it, and the regulatory status of any compounded product. If a platform is still advertising "compounded semaglutide" without explanation of how it complies with post-shortage regulations, that warrants caution.

Your Rights as a Patient

• You have the right to request a transition plan from your prescriber if you were on compounded semaglutide.
• You have the right to ask for a prior authorization appeal if your insurer denies Wegovy coverage.
• You have the right to request a documented individualized medical need evaluation if your prescriber believes a 503A-compounded formulation remains appropriate for you.
• You have the right to understand what you are being prescribed — ask for the ingredient list, the compounding pharmacy's 503A/503B designation, and their quality assurance practices.

Bottom Line

The FDA's March 2025 shortage resolution does not eliminate the demand for affordable semaglutide — it eliminates the easiest legal pathway that made it accessible. Patients who benefited from compounded semaglutide deserve clear, honest guidance about their options rather than being abandoned at a regulatory cliff. The best next step is a direct, informed conversation with a telehealth or in-person prescriber who understands both the regulatory landscape and your individual clinical needs.